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In mammalian cells, >25% of synthesized proteins are exported through the secretory pathway. The 23 pathway complexity, however, obfuscates its impact on the secretion of different proteins. Unraveling its 24
impact on diverse proteins is particularly important for biopharmaceutical production. Here we delineate 25 the core secretory pathway functions and integrate them with genome-scale metabolic reconstructions 26 of human, mouse, and Chinese hamster cells. The resulting reconstructions enable the computation of 27 energetic costs and machinery demands of each secreted protein. By integrating additional omics data, 28 we find that highly secretory cells have adapted to reduce expression and secretion of other expensive 29
host cell proteins. Furthermore, we predict metabolic costs and maximum productivities of biotherapeutic 30 proteins and identify protein features that most significantly impact protein secretion. Finally, the model 31
successfully predicts the increase in secretion of a monoclonal antibody after silencing a highly expressed 32 selection marker. This work represents a knowledgebase of the mammalian secretory pathway that serves 33 as a novel tool for systems biotechnology. 34
Introduction 38
To interact with their environment, cells produce numerous signaling proteins, hormones, receptors, 39 and structural proteins. In mammals, these include at least 2,641 secreted proteins (e.g., enzymes, 40 hormones, antibodies, extracellular matrix proteins) and >5,500 membrane proteins 1 , most of which are 41 synthesized and processed in the secretory pathway. 42
The secretory pathway consists of a complex series of processes that predominantly take place in the 43 endoplasmic reticulum (ER), Golgi apparatus, and the endomembrane system. This pathway is particularly 44 important in biotechnology and the biopharmaceutical industry, since most therapeutic proteins are 45 produced in mammalian cell lines such as HEK293, PerC6, NS0, and Chinese hamster ovary (CHO) cells, 46 which are capable of folding and adding the necessary post-translational modifications (PTMs) to the 47 target product 2 . For any given biotherapeutic, different machinery in the secretory pathway may be 48 needed, and each step can exert a non-negligible metabolic demand on the cells. The complexity of this 49 pathway, however, makes it unclear how the biosynthetic cost and cellular needs vary for different 50 secreted proteins, each of which exerts different demands for cellular resources. Therefore, a detailed 51 understanding of the biosynthetic costs of the secretory pathway could guide efforts to engineer host 52 cells and bioprocesses for any desired product. The energetic and material demands of the mammalian 53 secretory pathway can be accounted for by substantially extending the scope of metabolic models. 54 140
Validation of iCHO2048s growth and productivity predictions 141
We first validated the accuracy of iCHO2048s predictions using growth and specific productivity rates 142 of IgG-producing CHO cell lines from two independent studies 12, 18 . For this, we built an IgG-secreting 143 iCHO2048s model using the information in the PSIM matrix for the therapeutic mAb Rituximab. We then 144 constrained the model's Rituximab-specific secretory pathway with the reported productivity value in 145 each study and used FBA to predict growth (Fig. 3a) . Later, to assess the ability of iCHO2048s to predict 146 growth rates in cases when CHO cells are producing non-antibody proteins, we collected data from two 147 batch culture experiments using Enbrel-and C1-inhibitor-producing isogenic CHO cell lines. We 148 constructed two iCHO2048s models for each case and predicted growth rates during the early exponential 149 growth phase of culture while constraining the protein secretion rate to the measured specific 150 productivity value (Fig. 3b ). The model predictions agreed well with the reported and measured values. 151
There were cases where iCHO2048s predicted a much higher growth rate than what was measured in the 152 first days of batch culture (Fig. 3b ). Since FBA computes theoretical maximum growth rates given a set of 153 constraints, these over-prediction cases point at situations where CHO cells do not direct resources 154 towards biomass production (during very early stages of culture), a discrepancy that is attenuated in later 155 stages of culture. In conclusion, these results confirm the ability of protein-specific reconstructions to 156 capture the specific energetic requirements that each recombinant product imposes on CHO cell 157 metabolism. 158 159 Protein composition impacts predicted productivity 160 To produce a specific product, CHO cells may utilize different modules of the secretory pathway based 161 on the protein attributes and post-translational modifications (PTMs). For example, the synthesis of a mAb 162 requires the use of multiple processes and consumes several different metabolites, such as amino acids 6 for protein translation, redox equivalents for forming disulfide bonds, ATP equivalents for vesicular 164 transport, and sugar nucleotides for protein glycosylation (Fig. 2c ). Therefore, we generated eight 165 product-specific secretory pathway models for biotherapeutics commonly produced in CHO cells ( Fig. 4a) : 166 bone morphogenetic proteins 2 and 7 (BMP2, BMP7), erythropoietin (EPO), Enbrel, factor VIII (F8), 167 interferon beta 1a (IFNB1), Rituximab, and tissue plasminogen activator (tPA). The resulting iCHO2048s 168 models were used to compute Pareto optimality frontiers between maximum cell growth (μ) and specific 169 productivity (qP), given the same measured glucose and amino acid uptake rates for each model 17 (see 170
Supplementary Data 3). 171
We computed the tradeoff between growth rate (hours -1 ) and specific productivity (picogram of 172 protein produced per cell per day, or PCD) as a Pareto optimal curve for each protein (Fig. 4b ). This curve 173 defines the frontier of maximum specific productivity and maximum growth rates under the assumption 174 that CHO cells can utilize all available resources towards production of biomass and recombinant protein 175 only. The hinges in some of the curves are indicative of a transition between regions that are limited by 176 distinct protein requirements (e.g., amino acids). 177
An analysis of the Pareto optimal curves for the eight biotherapeutics demonstrates that under the 178 measured growth conditions, maximum productivities vary from 20-100 PCD at common growth rates 179 ( Fig. 4b , shaded region) to 70-150 PCD for senescent CHO cells. Neither the molecular weight (MW) nor 180 product length can explain the 2-fold range differences in maximum productivity for different proteins. 181
For example, the curves show tPA (MW = 61,917 Da) can express at higher PCD than BMP2 (MW = 44,702 182 Da) despite being larger, because the N-glycans in BMP2 reduce productivity due to the higher cost of 183 synthesizing core N-glycans (see Table 1 ), consistent with previous observations in yeast 5 . Furthermore, 184 the degree and directionality of these effects will depend on the nutrient uptake rates ( Figure 4c and 185 Supplementary Figure 1 ), highlighting the need in CHO bioprocessing to tailor culture media in a host cell 186 and product-specific manner. Thus, while intuitively larger proteins would be expected to exert more 187 bioenergetic cost on protein secretion, we find that specific compositional attributes of both the 188 recombinant protein and the culture media significantly impact biosynthetic capacity. An in-depth analysis 189 of the effects of PTMs on predicted productivities is provided in Jupyter Notebook C. 190
To further evaluate what functions of the secretory pathway had the greatest impact on the cost of 191 protein synthesis and secretion, we computed secretion rates for 5,461 proteins in the CHO secretome 192 (see Methods) using iCHO2048s and its parent metabolic reconstruction iCHO1766 17 . While iCHO2048s 193 captures all the required steps for protein synthesis, modification and secretion, the secretion reactions 194 in iCHO1766 only account for the basic synthesis of the target protein in cytoplasm, and the synthesis of 7 necessary precursors (N-linked glycans, O-linked glycans, and GPI anchors). We found that secretory 196 pathway had non-negligible costs on most proteins ( Supplementary Figure 3b ). Furthermore, protein 197 features associated with secreted proteins that differ in cost by >15% beyond the amino acid and glycan 198 costs show a statistical enrichment (under the Hypergeometric test) for O-linked glycans (p = 0.0065), GPI 199 anchors (p = 0.0216), transmembrane domains (p = 0.0326), and proteins destined to the ER lumen 200 (p=0.0142), the Golgi membrane (p = 0.0065), or the plasma membrane (p = 0.0186, see Supplementary 201 that could be used for antibody production, we predicted how much additional antibody could be 211 synthesized with the elimination of the neoR gene. We simulated antibody production following a 212 complete knockout of neoR (see Table 2 and Fig. 5b ) and predicted that the deletion of neoR could 213 increase specific productivity by up to 4% and 29% on days 3 (early exponential phase) and 6 (late phase) 214 of culture, respectively ( Fig. 5c ). This was qualitatively consistent with the experimentally observed values 215 of 2% and 14% when neoR mRNA was knocked down by 80-85%. We then computed the Pareto optimality 216 curves for both the control and the neoR in silico knockout conditions on day 6. We found that the length 217 of the curve (denoted by ) increased by 18% when neoR production is eliminated ( Fig. 5d ). Thus, 218 iCHO2048s can quantify how much non-essential gene knockouts can boost growth and productivity in 219 CHO cells by freeing energetic and secretory resources. In fact, the ribosome-profiling data from 220
Kallehauge et al. revealed that only 30 secretory proteins in CHO cells account for more than 50% of the 221 ribosomal load directed towards translation of protein bearing a signal peptide ( Fig. 4E ). Indeed, we 222 recently found that substantial resources can be liberated and recombinant protein titers can be increased 223 when 14 high-abundance host cell proteins were knocked out 20 . An analysis of other potential host cell 224 gene knockouts using the method proposed here can be found in Supplementary Data 4. Many of these proteins, including hormones, enzymes, and receptors, are essential for mediating 229 mammalian cell interactions with their environment. Therefore, many have therapeutic importance either 230 as drugs or as targets. The expression and secretion of recombinant proteins represents a significant 231 anabolic demand that drains several substrates from cellular metabolism (e.g., amino acids, sugar 232 nucleotides, ATP) 21, 22 . Furthermore, the recombinant proteins demand adequate expression of supporting 233 proteins involved in their transcription, translation, folding, modification, and secretion. Thus, there has 234 been an increasing interest in engineering the mammalian secretory pathway to boost protein 235 production [23] [24] [25] [26] . Despite important advances in the field 27 , current strategies to engineer the secretory 236 pathway have remained predominantly empirical 28, 29 . Recent modeling approaches, however, have 237 enabled the analysis of the metabolic capabilities of important eukaryotic cells under different genetic 238 and environmental conditions 17, [30] [31] [32] . With the development of genome-scale models of protein-producing 239 cells, such as CHO 17 , HEK-293 33 and hybridomas 34, 35 , it is now possible to gain a systems-level 240 understanding of the mammalian protein production phenotype 36 . 241
242
Efforts have been underway to enumerate the machinery needed for protein production. For 243 example, Lund and colleagues 6 recently reconstructed a comprehensive genetic network of the mouse 244 secretory pathway. By comparing the mouse and CHO-K1 genomes and mapping CHO gene expression 245 data onto this network, the authors identified potential targets for CHO cell engineering, demonstrating 246 the potential of systems biology to interrogate and understand protein secretion in animal cells. This 247 genetic network reconstruction, although useful for contextualizing omics data (e.g., RNA-Seq), is not set 248 up for simulations of protein production, nor integrated with additional cellular processes such as 249 metabolism. Therefore, our work is complementary in that it allows one to also to quantify the cost and 250 cellular capacity for protein production by delineating the mechanisms of all biosynthetic steps and 251 bioenergetic processes in the cell. 252
253
Here we presented the first genome-scale reconstruction of the secretory pathway in mammalian 254 cells coupled to metabolism. We connected this to current metabolic networks, yielding models of protein 255 secretion and metabolism for human, mouse and CHO cells. These models compile decades of research 256 in biochemistry and cell biology of higher eukaryotes and present it in a mathematical model. Using our 257 model, we quantitatively estimated the energetic cost of producing several therapeutic proteins and all 9 proteins in the CHO cell and human secretomes. We also identified factors limiting the secretion of 259 individual products and observed that these depend on both the complexity of the product and the 260 composition of the culture media. Furthermore, by integrating ribosomal profiling data with our model 261 we found that CHO cells have selectively suppressed the expression of energetically expensive secreted 262 proteins. Expanding upon this observation, we demonstrated that specific productivities can be 263 predictably increased following the knock-down of an energetically expensive, non-essential protein. 264
Furthermore, consistent with this, we have recently shown more than 50% reductions in total host cell 265 protein production, along with increases in mAb titer when deleting 14 highly abundant proteins in CHO 266 cells. Further studies will likely further explore how much of the CHO cell proteome can be deleted to 267 further enhance recombinant protein secretion 20 . 268
269
It is important to note that while our models capture major features of secreted proteins, there are 270 additional PTMs (e.g., phosphorylation, gamma carboxylation), pathway machinery (e.g., chaperones), 271
and cell processes that could possibly be captured in further expansions of the modeling framework 6 (e.g., 272
the unfolded protein response). These could be included as energetic costs associated with building and 273 maintaining the secretory machinery (chaperones 3 , disulfide oxidoreductases 37 , glycosyltransferases 38 ); 274 protein stability and turnover rates 39 ; solubility constraints 40 and molecular crowding effects 41 . As these 275 are captured by the models in a protein product-specific manner, predictions of protein production 276 capacity will improve, and the models could provide further insights for cell engineering for biotechnology 277 or to obtain a deeper understanding of mechanisms underlying amyloid diseases. Finally, a simplification 278 of our secretory model is that it only computes the bioenergetic cost of synthesizing and attaching single 279 representative N-and O-linked glycans to secreted proteins (i.e., it does not include the 280 microheterogeneity and diversity of glycan structures of different proteins). Thus, an immediate potential 281 expansion of our secretory model would involve coupling it to existing computational models of protein 282 glycosylation 42,43 . For example, given an N-glycan reaction network that captures the glycoform 283 complexity of a target protein 44 , one could build secretory reactions for the specific glycoforms of interest 284 and compute the metabolic demands associated with each of them to identify potential targets and 285 nutrient supplementations for glycoengineering. 286
287
In conclusion, the results of our study have important implications regarding the ability to predict 288 protein expression based on protein specific attributes and energetic requirements. The secretory 289 pathway models here stand as novel tools to study mammalian cells and the energetic trade-off between 290 growth and protein secretion in a product-and cell-specific manner. We presented algorithms that 291 provide novel insights with our models, and expect that many other methods can be developed to answer 292 a wide array of questions surrounding the secretory pathway, as seen for metabolism 45 . To facilitate 293 further use of these models, we provide our code and detailed instructions on how to construct protein- is hydrolyzed to GDP for every 40 amino acids that pass through the translocon pore 46 . Thus, the cost of 405 translocation is (L÷40) + 2. 406
Energetic cost of vesicular transport and secretion: We used published data 51-53 (see Supplementary Data 407 1) to compute stoichiometric coefficients for reactions involving vesicular transport. That is, the number 408 of GTP molecules bound to RAB and coat proteins in each type of vesicle (COPII and secretory vesicles). 409
We found that a total of 192 and 44 GTPs must be hydrolyzed to transport one COPII or secretory (i.e. 410 clathrin coated) vesicle from the origin membrane to the target membrane, respectively. Since vesicles 411 do not transport a single protein molecule at a time, we estimated the number of secreted protein 412 molecules that would fit inside a spherical vesicle (see estimated and assumed diameters in the 413 Supplementary Data 1). For that, we assumed that the secreted protein is globular and has a volume VP 414 (nm 3 ) that is directly proportional to its molecular weight MW 54 : 415
Finally, we assumed that only 70 percent of the vesicular volume can be occupied by the target protein. 
Analysis of gene expression versus protein cost
429 Ribosome-profiling data 12 were used to quantify the ribosomal occupancy of each transcript in CHO 430 cells. A cutoff of 1 RPKM was used to remove genes with low expression (10,045 genes removed from day 431 3 analysis and 10,411 from day 6 analysis). We used Spearman correlation to assess the variation of 432 expression levels with respect to protein ATP cost. 433
434

CHO-DG44 model and prediction of neoR knock-out effect 435
Ribosome-profiling data, specific productivity, product sequence, and growth rates of an IgG-436 producing CHO-DG44 cell line were obtained from a previous publication 12 Finally, a reaction of neoR peptide translation (which is expressed in cytosol and is not processed in 446 the secretory pathway) was added to construct a neoR-specific iCHO2048s model. Uptake and secretion 447 rates of relevant metabolites on days 3 and 6 of cell culture were used to constrain our model. Because 448 recombinant proteins represent 20% of total cell protein 57 , we scaled the coefficients of all 20 amino acids 449 in the model's biomass reaction accordingly (i.e. each coefficient was multiplied by 0.8). We then used 450 FBA to predict the specific productivity of IgG with or without neoR. 
Calculation of growth and productivity rates 461
Supplementary Data 3 contains the experimental uptake and secretion rates used to constrain the 462 iCHO2048s models 12, 22, 23 . When rates were not explicitly stated in the studies we consulted, we used a 463 method we developed previously 27 representative biotherapeutics produced in CHO cells are shown for comparison purposes (see Table 1 ). 643 Growth rates were computed using an IgG-specific iCHO2048s model and compared to experimentally 667 measured growth rates from six datasets from two previous studies using IgG-producing cell lines 12, 18 . NT 668 and TK specify the initials of the first author of the two studies (Neil Templeton, Thomas Kallehauge). (b) 669
Additional growth, productivity, and metabolomic data were obtained from Enbrel and C1INH-producing 670 CHO cells, and models were constructed. The model-predicted growth rates during exponential growth 671 phase were consistent with experimental growth rates of Enbrel-producing CHO cells and C1INH-672 producing CHO cells at almost all time points. In all cases, the iCHO2048s models were constrained to 673 produce the recombinant protein at the measured specific productivity rate. The values used to constrain 674 to quantify the contribution of PTMs to the explained variation in speci c productivity using uptake rates di erent from those used in Figure 4c . The speci c consumption rates are listed in Supplementary Table 3 
Factors Explained variation (β)
Supplementary Discussion
Overview of the Secretory Pathway in animal cells
Historically, most of the knowledge on the secretory pathway was obtained by studying protein transport processes and secretion in Saccharomyces cerevisiae 1 . Albeit quite similar in core functions, the secretory pathways of mammalian cells and fungi differ significantly in some of the steps which have been evolved based on species-specific secretion phenotypes 2 . The following paragraphs briefly overview the mammalian secretory pathway and highlights pathways exclusive to animals not present in fungi. The last section provides an in-depth comparison of the yeast and animal secretory pathways while highlighting the most important differences between both.
Translocation and processing in endoplasmic reticulum
Proteins destined to the secretory pathway generally bear a signal peptide at the amino-terminus which targets the proteins to the endoplasmic reticulum (ER) where the initial post-translational modifications (PTMs) take place. This transport requires translocating the target protein across the ER membrane through two general pathways: co-translational translocation (GTP dependent) and post-translational translocation (ATP dependent) 3 . An additional pathway for tail-anchored (TA) proteins into the ER membrane has also been discussed in the literature and included in our iCHO1921s reconstruction 4, 5 .
Once inside the ER lumen, the target proteins are folded by the action of several transmembrane ER proteins, including calnexin, calreticulin, and other luminal chaperones [6] [7] [8] . In the event of protein misfolding, a target protein may go through a "quality control" system (exclusive in the mammalian secretory pathway) that attempts to correct for folding errors 9, 10 . However, if the misfolded state of the protein is sustained for too long, the protein then enters the ER associated degradation pathway, or ERAD, which involves retrotranslocation of the misfolded protein back to the cytosol, ubiquitination and proteasomal degradation [11] [12] [13] .
Besides folding, a target protein may acquire additional PTMs while inside the ER such as attachment of a glycosylphosphatidylinositol (GPI) anchor 14, 15 , formation of disulfide bonds 16 , and N-linked glycosylation [17] [18] [19] [20] . After these PTMs are successfully completed , the target proteins are transported to the Golgi apparatus via COPII-coated vesicles that bud from the ER 21, 22 whereas misfolded proteins are retrotranslocated to the cytoplasm 23, 24 for proteasomal degradation via the ER-associated degradation pathway (ERAD) 25, 26 . In the Golgi apparatus, N-glycans are processed into branched and complex glycoforms and proteins are further glycosylated with O-linked glycans [27] [28] [29] and then sorted to their final destination (e.g. lysosome, extracellular medium) via clathrin-coated secretory vesicles [30] [31] [32] [33] .
A note on translocation pathways
In co-translational translocation, proteins destined to the secretory pathway bear a hydrophobic signal sequence at the amino-terminus that promotes the targeting of ribosome-nascent chain (RNC) complexes to the ER via binding to the signal recognition particle (SRP). The SRP recognizes the signal peptide as soon as it emerges from the ribosome during translation. Then, the newly formed SRP-RNC complex is recognized by the SRP receptor on the ER membrane where translocation is initiated by interaction with the Sec61 complex (Sec61C) and assisted by the chaperone BiP to increase the efficiency and ensure the unidirectionality of this process 30 .
Post-translational translocation, in contrast to co-translational translocation, occurs independently of SRP and its receptor 34 . Furthermore, this process does not rely too heavily on the Sec61C to translocate the target protein and instead utilizes the protein Sec62 as a safe route that guarantees the efficient translocation of small proteins (<160 amino acids in length) 35 .
Finally, the pathway for inserting TA proteins into the ER membrane also occurs post-translationally due to the fact that the ER targeting signal of TA proteins is located very close to the carboxy-terminus, which allows the ribosome to release the protein before it is recognized and localized to the ER 36 . This pathway depends on ATP and one of the main players in the process is a transmembrane recognition complex known as TRC40 or Asna1 37 .
Important differences between the yeast and animal secretory pathways
As mentioned above, core functions of the secretory pathway are conserved between mammalian and yeast cells. These core functions (see Table SD .2) are:
• Translocation through endoplasmic reticulum
• Primary glycosylation in ER (N-linked glycans) and Golgi (N-linked and O-linked glycans)
• Protein folding and quality control in ER
• Anterograde and retrograde vesicular transport between ER and Golgi via COPII and COPI vesicles, respectively.
• Dolichol pathway for N-linked core glycan translocation through the ER membrane
• Endoplasmic reticulum associated degradation (ERAD)
• GPI biosynthesis
• Unfolded protein response (UPR)
Nevertheless, minor and major differences exist between the yeast and mammalian secretory pathways.
Some of these differences have been thoroughly reviewed before in an excellent review by Delic and colleagues 2 and are summarized in Table SD .1 below. Here, we highlight the major differences between both secretory pathways that are relevant for modeling purposes using the secretory reconstructions. Finally, the table below summarizes the differences between the mammalian and the fungal secretory pathway reconstructions in terms of components, reactions, and subsystems. 
